2. Antibody-drug Conjugate/ADC Related
  3. Radionuclide-Drug Conjugates (RDCs)
  4. PTP peptide

PTP peptide is a specific Plectin-1 binder. PTP peptide can serve as a component of imaging agents; when conjugated with magnetofluorescent nanoparticles, it enables the detection of small pancreatic ductal adenocarcinomas and precancerous lesions via in vivo confocal microscopy and MRI. When conjugated with imaging agents, PTP peptide specifically targets pancreatic ductal adenocarcinoma cells, and can be used for tumor visualization and compound delivery. PTP peptide is applicable to research related to pancreatic ductal adenocarcinoma.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

PTP peptide

PTP peptide Chemical Structure

CAS No. : 1192023-11-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PTP peptide Related Antibodies

Top Publications Citing Use of Products

View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

View All Isoforms
RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PTP peptide is a specific Plectin-1 binder. PTP peptide can serve as a component of imaging agents; when conjugated with magnetofluorescent nanoparticles, it enables the detection of small pancreatic ductal adenocarcinomas and precancerous lesions via in vivo confocal microscopy and MRI. When conjugated with imaging agents, PTP peptide specifically targets pancreatic ductal adenocarcinoma cells, and can be used for tumor visualization and compound delivery. PTP peptide is applicable to research related to pancreatic ductal adenocarcinoma[1][2][3].

IC50 & Target[1]

RDC Peptide

 

In Vitro

The PTP peptide (1 h) displayed on phage clone 27 exhibits strong and specific binding to pancreatic ductal adenocarcinoma (PDAC) cells (MNA, 8988, SW1990, MIA-PaCa-2, ASPC), while its binding to normal ductal cells is extremely weak[2].
After being displayed on phage clone 27, the PTP peptide (1 h) specifically binds to in vitro mouse PanIN lesion tissues and mouse PDAC lesion tissues, but does not bind to normal pancreatic tissues[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PTP peptide Related Antibodies
In Vivo

[68Ga]Ga-NOTA-PTP (7.4-9.6 MBq; intravenous injection; single dose) accumulates rapidly and selectively in podoplanin-1-expressing CFPAC-1 pancreatic ductal adenocarcinoma xenografts, with an uptake of 1.65 %ID/g at 0.5 h post-injection[1].
[68Ga]Ga-NOTA-PTP (intravenous injection; single dose) specifically accumulates in netrin-1-expressing KPC pancreatic ductal adenocarcinoma xenografts, with a peak uptake of 2.69 %ID/g at 0.5 h post-injection, and exhibits a favorable tumor-to-background ratio by 1.5 h[1].
[68Ga]Ga-NOTA-PTP (intravenous injection; single dose; 0.925-9.6 MBq) shows extremely low uptake in MIN-6 pancreatic ductal adenocarcinoma xenografts with low netrin-1 expression, reaching 0.69 %ID/g at 0.5 h post-injection[1].
[68Ga]Ga-NOTA-PTP (7.4-9.6 MBq; intravenous injection; single dose) enables clear visualization of orthotopic pancreatic ductal adenocarcinoma and peritoneal metastases in KPC mice at 45 min post-injection, and exhibits superior tumor-to-background contrast compared with 2-[18F]FDG[1].
[68Ga]Ga-NOTA-PTP (7.4-9.6 MBq; intravenous injection; single dose) accumulates in plectin-1-expressing 4T1 breast cancer xenografts, with distinct uptake detectable at 30 min post-injection[1].
After conjugation of PTP peptide (administered via tail vein injection) with ICG to form ICG-PTP, the conjugate is administered to mice. At 24 h, it reaches a T/N ratio of 6.74 in subcutaneous PDAC tumors, enabling precise fluorescence-guided surgical resection with no postoperative tumor recurrence, and effectively mediating photothermal ablation to increase the tumor temperature by 13.0 °C[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female, 18−20 g, subcutaneous xenograft via injection of 5×10^6 CFPAC-1 cells)[1]
Dosage: 7.4−9.6 MBq ([68Ga]Ga-NOTA-PTP); 0.46 μmol (unlabeled NOTA-PTP)
Administration: i.v.; single dose; i.v.; single coadministered dose
Result: Visualized tumors distinctly as early as 0.5 h postinjection, with tracer uptake measured at 1.65 %ID/g, decreasing to 0.86 %ID/g at 90 min.
Significantly inhibited tumor uptake to 0.35 %ID/g at 1 h postadministration when excess unlabeled NOTA-PTP was co-administered.
Animal Model: C57BL/6 (18−20 g, subcutaneous xenograft via injection of 2.5×10^6 KPC cells)[1]
Dosage: 7.4−9.6 MBq (imaging); 0.925−1.11 MBq (biodistribution)
Administration: i.v.; single dose
Result: Showed significant tracer accumulation in tumors, with uptake of 1.75 %ID/g at 30 min postinjection via PET imaging.
Confirmed peak tumor uptake of 2.69 %ID/g at 0.5 h, decreasing to 1.53 %ID/g at 1 h and 0.91 %ID/g at 1.5 h via biodistribution analysis.
Achieved tumor-to-normal organ ratios at 1.5 h including tumor/muscle (4.38), tumor/liver (1.30), tumor/blood (3.57), and tumor/heart (2.66).
Animal Model: BALB/c nude (female, 18−20 g, subcutaneous xenograft via injection of 5×10^6 MIN-6 cells)[1]
Dosage: 7.4−9.6 MBq (imaging); 0.925−1.11 MBq (biodistribution)
Administration: i.v.; single dose
Result: Showed minimal tracer accumulation in tumors, with uptake of 0.44 %ID/g at 30 min postinjection via PET imaging.
Confirmed tumor uptake of 0.69 %ID/g at 0.5 h, decreasing to 0.37 %ID/g at 1 h and 0.32 %ID/g at 1.5 h via biodistribution analysis.
Animal Model: C57BL/6 (18−20 g, orthotopic model via injection of KPC cells into pancreatic parenchyma; peritoneal metastasis model)[1]
Dosage: 7.4−9.6 MBq
Administration: i.v.; single dose
Result: Clearly visualized both orthotopic pancreatic tumors and small peritoneal metastases at 45 min postinjection, with low background signal in major healthy organs, providing higher contrast than 2-[18F]FDG.
Animal Model: BALB/c (18−20 g, subcutaneous xenograft via injection of 4T1 cells into right hind limb)[1]
Dosage: 7.4−9.6 MBq
Administration: i.v.; single dose
Result: Demonstrated definite tracer uptake in 4T1 tumor sites at 30 min postinjection.
Molecular Weight

768.94

Formula

C36H64N8O10
CAS No.
Sequence

Lys-Thr-Leu-Leu-Pro-Thr-Pro
Sequence Shortening

KTLLPTP
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PTP peptide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PTP peptide1192023-11-2Radionuclide-Drug Conjugates (RDCs)Pan-02 pancreatic ductal adenocarcinoma cellshuman PDAC tissue sectionsmouse PDAC lesionsplectin-1HPDE6-C7 pancreatic ductal cellsnormal pancreatic ductal cellsPanIN lesionshuman PDAC cell linespancreatic ductal adenocarcinoma cellsmouse PDAC cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PTP peptide
Cat. No.:
HY-P11850
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.